AI superforecasting tools could revolutionize regulatory bodies like the FDA by providing objective predictions on project success and market viability. Currently, the FDA relies on subjective human judgment, leading to lengthy delays and conservative approaches from drug developers. By integrating AI-driven forecasts, institutions could make more informed strategic decisions, potentially accelerating innovation and reducing costs in fields like clinical trials. AI
IMPACT Could lead to more objective and efficient decision-making in regulatory bodies, accelerating innovation and reducing costs.
RANK_REASON Opinion piece discussing the potential application of AI superforecasting to regulatory bodies, rather than a direct release or product announcement.
Read on Astral Codex Ten (Scott Alexander) →
- 1DaySooner
- AI superforecasting
- Biogen
- Josh Morrison
- Nate Silver
- Scott Alexander
- United States Food and Drug Administration
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →